doxazosin has been researched along with Diabetes Mellitus, Type 2 in 33 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this trial was to evaluate the effect of doxazosin as add-on therapy in patients with hypertension not adequately controlled on current antihypertensive therapy, and impaired glucose metabolism." | 9.12 | Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. ( Ciccariello, L; Gussoni, G; Muggeo, M; Perrone, F; Pessina, AC; Scotti, A; Stoico, V, 2006) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 9.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 7.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "Doxazosin was taken orally once at bedtime for 1 to 3 months." | 6.71 | The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. ( Ikarashi, T; Kamoi, K, 2005) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 6.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 5.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| " The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 5.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this trial was to evaluate the effect of doxazosin as add-on therapy in patients with hypertension not adequately controlled on current antihypertensive therapy, and impaired glucose metabolism." | 5.12 | Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. ( Ciccariello, L; Gussoni, G; Muggeo, M; Perrone, F; Pessina, AC; Scotti, A; Stoico, V, 2006) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 5.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "Doxazosin (tonocardin) treatment was given for 11 weeks to 33 NIDDM patients with concomitant hypertension." | 5.08 | [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus]. ( Lazebnik, LB; Melichenko, SB; Serebrov, AN, 1998) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| " We assessed the effects of doxazosin on 24-h BP and spectral analysis of heart rate variability in hypertensive Type 2 diabetic patients with macroalbuminuria and compared the results with those in hypertensive Type 2 diabetic patients with normoalbuminuria and non-diabetic patients with essential hypertension." | 3.73 | Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. ( Hasegawa, K; Kuji, T; Ogawa, N; Shimura, G; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 3.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "To examine the effect of the alpha 1-adrenoblocker tonocardin (doxazosin) on the course of arterial hypertension (AH) and on carbohydrate and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus (DM) concurrent with AH." | 3.71 | [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension]. ( Balabolkin, MI; Khasanova, ER; Kreminskaia, VM; Trukhina, TV, 2002) |
| " With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
| "Doxazosin was taken orally once at bedtime for 1 to 3 months." | 2.71 | The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. ( Ikarashi, T; Kamoi, K, 2005) |
| "CARDIOVASCULAR RISK OF LEFT VENTRICULAR HYPERTROPHY: Because of the rhythmic, mechanical and ischemic risk related to it, the left ventricular hypertrophy (LVH) is considered to be a major independent risk factor for cardiovascular disease which should be screened for and treated early." | 2.70 | [Management of hypertensive patients with left ventricular hypertrophy]. ( Ambrosioni, E, 2002) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | 2.68 | Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment. ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 2.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| "Determine if men with type 2 diabetes who take α-blockers (ABs) for benign prostatic hypertrophy gain additional benefit with reduced diabetic complications." | 1.42 | Effects of α-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( Graybill, SD; Vigersky, RA, 2015) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 1.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| "Doxazosin (2 to 4 mg) was administered alone or with other previously received antihypertensive drugs for 6 months." | 1.31 | Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. ( Adachi, M; Hirano, T; Kashiwazaki, K; Yoshino, G, 2001) |
| " The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 1.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 16 (48.48) | 18.2507 |
| 2000's | 13 (39.39) | 29.6817 |
| 2010's | 3 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mills, CE | 2 |
| Govoni, V | 2 |
| Faconti, L | 2 |
| Casagrande, ML | 1 |
| Morant, SV | 1 |
| Webb, AJ | 2 |
| Cruickshank, JK | 2 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Graybill, SD | 1 |
| Vigersky, RA | 1 |
| Ambrosioni, E | 1 |
| Hoogenberg, K | 1 |
| van der Tuin, J | 1 |
| Janssen, CA | 1 |
| Balabolkin, MI | 1 |
| Khasanova, ER | 1 |
| Trukhina, TV | 1 |
| Kreminskaia, VM | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| Gaddi, A | 1 |
| Mugellini, A | 1 |
| Ciccarelli, L | 1 |
| Fogari, R | 1 |
| Kamoi, K | 1 |
| Ikarashi, T | 1 |
| Yasuda, G | 1 |
| Hasegawa, K | 1 |
| Kuji, T | 1 |
| Ogawa, N | 1 |
| Shimura, G | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Pessina, AC | 1 |
| Ciccariello, L | 1 |
| Perrone, F | 1 |
| Stoico, V | 1 |
| Gussoni, G | 1 |
| Scotti, A | 1 |
| Muggeo, M | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Kobalava, ZhD | 1 |
| Dominguez, LJ | 1 |
| Weinberger, MH | 1 |
| Cefalu, WT | 1 |
| Jacobs, DB | 1 |
| Barbagallo, M | 1 |
| Walsh, MF | 1 |
| Sowers, JR | 1 |
| Giorda, C | 1 |
| Appendino, M | 1 |
| Mason, MG | 1 |
| Imperiale, E | 1 |
| Pagano, G | 1 |
| Giordano, M | 3 |
| Matsuda, M | 1 |
| Sanders, L | 1 |
| Canessa, ML | 3 |
| DeFronzo, RA | 3 |
| Maheux, P | 1 |
| Facchini, F | 1 |
| Jeppesen, J | 1 |
| Greenfield, MS | 1 |
| Clinkingbeard, C | 1 |
| Chen, YD | 1 |
| Reaven, GM | 1 |
| Sanders, LR | 1 |
| Castellino, P | 2 |
| Evans, M | 1 |
| Perera, PW | 1 |
| Donoghue, J | 1 |
| Solini, A | 1 |
| Lazebnik, LB | 1 |
| Melichenko, SB | 1 |
| Serebrov, AN | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 1 |
| Reddi, AS | 2 |
| Nimmagadda, VR | 2 |
| Lefkowitz, A | 1 |
| Kuo, HR | 1 |
| Bollineni, JS | 1 |
| Casciano, J | 1 |
| Doyle, J | 1 |
| Casciano, R | 1 |
| Kopp, Z | 1 |
| Marchant, N | 1 |
| Bustacchini, S | 1 |
| Arikian, S | 1 |
| Kim, R | 1 |
| Arora, R | 1 |
| Hirano, T | 1 |
| Yoshino, G | 1 |
| Kashiwazaki, K | 1 |
| Adachi, M | 1 |
| Bodansky, HJ | 1 |
| Huupponen, R | 1 |
| Lehtonen, A | 1 |
| Vähätalo, M | 1 |
| Taylor, SH | 1 |
| Nosadini, R | 1 |
| Crepaldi, G | 2 |
| D'Angelo, A | 2 |
| Feher, MD | 2 |
| Henderson, AD | 1 |
| Wadsworth, J | 1 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 1 |
| Sever, PS | 1 |
| Elkeles, RS | 1 |
| Castrignano, R | 1 |
| Pati, T | 1 |
| Al Awady, M | 1 |
| Tronca, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for doxazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
Doxazosin therapy in the treatment of diabetic hypertension.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Lipids; Lipopro | 1991 |
13 trials available for doxazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Doxazosin; | 2017 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
Topics: Adult; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-B | 2005 |
The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements.
Topics: Adrenergic alpha-Antagonists; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Blood Pres | 2005 |
Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Are | 2006 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 1995 |
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1996 |
Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Antiporters; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; D | 1997 |
[Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Hemodynamics; Humans; H | 1998 |
Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
18 other studies available for doxazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of α-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin- | 2015 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2002 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2003 |
[Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucos | 2002 |
Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Blood Pre | 2005 |
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |
Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Erythrocytes; Female; Humans; H | 1995 |
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1995 |
Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus.
Topics: Apolipoproteins; Blood Glucose; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hypertension; | 1994 |
Drug induced psychosis with doxazosin.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hypertension; P | 1997 |
Effect of antihypertensive therapy on renal injury in type 2 diabetic rats with hypertension.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Typ | 2000 |
The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Do | 2001 |
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Ag | 2001 |
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Topics: Aged; Antihypertensive Agents; Apolipoproteins; Blood Glucose; Blood Pressure; C-Peptide; Cholestero | 2001 |
Doxazosin: alternative antihypertensive treatment.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hyper | 1992 |
Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Heart Rate; Human | 1992 |
Diabetes mellitus and hypertension: a physiologic basis for a rational therapeutic approach.
Topics: Antihypertensive Agents; Biological Transport; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1991 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |